Gene therapy for cystic fibrosis

Bibliography

• BALLARD ST, TROUT L, BEBOK Z, SORSCHER EJ, CREWS A: CFTR involvement in chloride, bicarbonate and liquid secretion by airway submucosal glands. Am. J. Physiol (1999) 277:L694–L699.
   PubMed Web of Science ®Google Scholar
• CANTIELLO HF, JACKSON GR JR., GROSMAN CF et al.: Electrodiffusional ATP movement through the cystic fibrosis transmembrane conductance regulator. Am. J. Physic)]. (1998) 274:C799–C809.
   Google Scholar
• HIGGINS CF: The ABC of channel regulation. Cell (1995) 82:693–696.
   PubMed Web of Science ®Google Scholar
• GADSBY DC, NAIRN AC: Regulation of CFTR channel gating. Trends Biochem. Sci. (1994) 19:513–518.
   PubMed Web of Science ®Google Scholar
• FRIEDMANN T: A brief history of gene therapy. Nature Genet. (1992) 2:93–98.
   PubMed Web of Science ®Google Scholar
• ROMMENS JM, IANNUZZI MC, KEREM B et al: Identifica-tion of the cystic fibrosis gene: chromosome walking and jumping. Science (1989) 245:1059–1065.
   PubMed Web of Science ®Google Scholar
• DIAMOND G, SCANLIN TF, ZASLOFF MA, BEVINS CL: A cross-species analysis of the cystic fibrosis transmem-brane conductance regulator. Potential functional domains and regulatory sites. J. Biol. Chem. (1991) 266:22761–22769.
   PubMed Web of Science ®Google Scholar
• KEREM B, ROMMENS JM, BUCHANAN JA et al.: Identifica-tion of the cystic fibrosis gene: genetic analysis. Science (1989) 245:1073–1080.
   PubMed Web of Science ®Google Scholar
• RIORDAN JR, ROMMENS JM, KEREM B et al.: Identifica-tion of the cystic fibrosis gene: cloning and characteri-zation of complementary. Science (1989) 245:1066–1073.
   PubMed Web of Science ®Google Scholar
• EGAN M, FLOTTE T, AFIONE S et al: Defective regulation of outwardly rectifying Cl- channels by protein kinase A corrected by insertion of CFTR. Nature (1992) 358:581–584.
   PubMed Web of Science ®Google Scholar
• STUTTS MJ, CANESSA CM, OLSEN JC et al: CFTR as acAMP-dependent regulator of sodium channels. Science (1995) 269:847–850.
   PubMed Web of Science ®Google Scholar
• GOLDMAN MJ, ANDERSON GM, STOLZENBERG ED, KARI UP, ZASLOFF M, WILSON JM: Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell (1997) 88:553–560.
   PubMed Web of Science ®Google Scholar
• DAVIES JC, STERN M, DEWAR A: CFTR gene transfer reduces the binding of Pseudomonas aeruginosa to cystic fibrosis respiratory epithelium. Am. J. Respir. Cell Mol. Biol. (1997) 16:657–663.
   PubMed Web of Science ®Google Scholar
• HOOGERBRUGGE PM, VON BEUSECHEM VW, KAPTEINLC, EINERHAND MP, VALERIO D: Gene therapy for adenosine deaminase deficiency. Br. Med. Bull. (1995) 51 :72–81.
   PubMed Web of Science ®Google Scholar
• DRUMM ML, POPE HA, CLIFF WH et al.: Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell (1990) 62:1227–1233.
   PubMed Web of Science ®Google Scholar
• BERGELSON JM, CUNNINGHAM JA, DROGUETT G et al.: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (1997) 275:1320–1323.
   PubMed Web of Science ®Google Scholar
• GREBER UF, WILLETTS M, WEBSTER P, HELENIUS A:Stepwise dismantling of adenovirus 2 during entry into cells. Cell (1993) 75:477–486.
   PubMed Web of Science ®Google Scholar
• YANG Y, NUNES FA, BERENCSI K, GONCZOL E, ENGELHARDT JF, WILSON JM: Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genet. (1994) 7:362–369.
   PubMed Web of Science ®Google Scholar
• YEH P, PERRICAUDET M: Advances in adenoviralvectors: from genetic engineering to their biology. FASEB J (1997) 11:615–623.
   PubMed Web of Science ®Google Scholar
• KAPLAN JM, ARMENTANO D, SPARER TE et al: Charac-terization of factors involved in modulating persis-tence of transgene expression from recombinant adenovirus in the mouse lung. Hum. Gene Ther. (1997) 8:45–56.
   PubMed Web of Science ®Google Scholar
• FLOTTE TR, CARTER BJ: Adeno-associated virus vectors for gene therapy. Gene Ther. (1995) 2:357–362.
   PubMed Web of Science ®Google Scholar
• FELGNER PL, GADEK TR, HOLM M et al.: Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. ScL USA (1987) 84:7413–7417.
   PubMed Web of Science ®Google Scholar
• GAO X, HUANG L: A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem. Biophys. Res. Commun. (1991) 179:280–285.
   PubMed Web of Science ®Google Scholar
• LEE ER, MARSHALL J, SIEGEL CS et al.: Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. Hum. Gene Ther. (1996) 7:1701–1717.
   PubMed Web of Science ®Google Scholar
• FELGNER PL: Improvements in cationic liposomes for in vivo gene transfer. Hum. Gene Ther. (1996) 7:1791–1793.
   PubMed Web of Science ®Google Scholar
• GERSHON H, GHIRLANDO R, GUTTMAN SB, MINSKY A: Mode of formation and structural features of DNA-cationic liposome complexes used for transfec-tion. Biochemistry (1993) 32:7143–7151.
   PubMed Web of Science ®Google Scholar
• STERNBERG B, SORGI FL, HUANG L: New structures in complex formation between DNA and cationic liposomes visualized by freeze-fracture electron microscopy. FEBS Lett. (1994) 356:361–366.
   PubMed Web of Science ®Google Scholar
• FERRARI S, MORO E, PETTENAZZO A, BEHR JP, ZACCHELLO F, SCARPA M: ExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo. Gene Ther. (1997) 4:1100–1106.
   PubMed Web of Science ®Google Scholar
• ZABNER J, ZEIHER BG, FRIEDMAN E, WELSH MJ: Adenovirus-mediated gene transfer to ciliated airway epithelia requires prolonged incubation time. J. Vim]. (1996) 70:6994–7003.
   Web of Science ®Google Scholar
• GRUBB BR, PICKLES RJ, YE H et al.: Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature (1994) 371:802–806.
   PubMed Web of Science ®Google Scholar
• GOLDMAN MJ, WILSON JM: Expression of avOs integrinis necessary for efficient adenovirus-mediated gene transfer in the human airway. J. ViroL (1995) 69:5951–5958.
   PubMed Web of Science ®Google Scholar
• HARVEY BG, WORGALL S, ELY S, LEOPOLD PL, CRYSTALRG: Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- adenovirus gene transfer vector. Hum. Gene Ther. (1999) 10:2823–2837.
   PubMed Web of Science ®Google Scholar
• KAPLAN JM, SMITH AE: Transient immunosuppressionwith deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung. Hum. Gene Ther. (1997) 8:1095–1104.
   PubMed Web of Science ®Google Scholar
• MACK CA, SONG WR, CARPENTER H et al: Circumven-tion of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum. Gene Ther. (1997) 8:99–109.
   PubMed Web of Science ®Google Scholar
• VAN GINKEL FW, LIU C, SIMECKA JAN et al.: Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase. Hum. Gene Ther. (1995) 6:895–903.
   PubMed Web of Science ®Google Scholar
• LEVENTIS R, SILVIUS JR: Interactions of mammalian cells with lipid dispersions containing novel metabo-lizable cationic amphiphiles. Biochim. Biophys. Acta (1990) 1023:124–132.
   PubMed Web of Science ®Google Scholar
• FRIEND DS, PAPAHADJOPOULOS D, DEBS RJ: Endocy-tosis and intracellular processing accompanying transfection mediated by cationic liposomes. Biochim. Biophys. Acta (1996) 1278:41–50.
   PubMed Web of Science ®Google Scholar
• MISLICK KA, BALDESCHWIELER JD: Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc. Natl. Acad. Sci. USA (1996) 93:12349–12354.
   PubMed Web of Science ®Google Scholar
• FARHOOD H, SERBINA N, HUANG L: The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim. Biophys. Acta (1995) 1235:289–295.
   PubMed Web of Science ®Google Scholar
• XU Y, SZOKA FC JR.: Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry (1996) 35:5616–5623.
   Google Scholar
• ZABNER J, FASBENDER AJ, MONINGER T, POELLINGER KA, WELSH MJ: Cellular and molecular barriers to gene transfer by a cationic lipid. J. Biol. Chem. (1995) 270:18997–19007.
   PubMed Web of Science ®Google Scholar
• MATSUI H, JOHNSON LG, RANDELL SH, BOUCHER RC:Loss of binding and entry of liposome-DNA complexes decreases transfection efficiency in differentiated airway epithelial cells. J. Biol. Chem. (1 99 7) 272:1117-1126.
   Google Scholar
• ROSENFELD MA, YOSHIMURA K, TRAPNELL BC et al.: In vivo transfer of the human cystic fibrosis transmem-brane conductance regulator gene to the airway epithelium. Cell (1992) 68:143–155.
   PubMed Web of Science ®Google Scholar
• BRODY SL, METZGER M, DANEL C, ROSENFELD MA, CRYSTAL RG: Acute responses of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conduc-tance regulator cDNA. Hum. Gene Ther. (1994) 5:821–836.
   PubMed Web of Science ®Google Scholar
• ZABNER J, PETERSEN DM, PUGA AP et al.: Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nature Genet. (1994) 6:75–83.
   PubMed Web of Science ®Google Scholar
• KOLLER BH, KIM HS, LATOUR AM et al.: Toward an animal model of cystic fibrosis: targeted interruption of exon 10 of the cystic fibrosis transmembrane regulator gene in embryonic stem cells. Proc. Natl. Acad. ScL USA (1991) 88:10730–10734.
   PubMed Web of Science ®Google Scholar
• SNOUWAERT JN, BRIGMAN KK, LATOUR AM et al.: An animal model for cystic fibrosis made by gene targeting. Science (1992) 257:1083–1088.
   PubMed Web of Science ®Google Scholar
• CLARKE LL, GRUBB BR, GABRIEL SE, SMITHIES O, KOLLER BH, BOUCHER RC: Defective epithelial chloride transport in a gene-targeted mouse model of cystic fibrosis. Science (1992) 257:1125–1128.
   PubMed Web of Science ®Google Scholar
• RATCLIFF R, EVANS MJ, CUTHBERT AW et al.: Production of a severe cystic fibrosis mutation in mice by gene targeting. Nature Genet. (1993) 4:35–41.
   PubMed Web of Science ®Google Scholar
• DORIN JR, DICKINSON P, ALTON EW et al: Cystic fibrosis in the mouse by targeted insertional mutagenesis. Nature (1992) 359:211–215.
   PubMed Web of Science ®Google Scholar
• DORIN JR, STEVENSON BJ, FLEMING S, ALTON EW, DICKINSON P, PORTEOUS DJ: Long-term survival of the exon 10 insertional cystic fibrosis mutant mouse is a consequence of low level residual wild-type Cftr gene expression. Mamm. Genome (1994) 5:465–472.
   PubMed Web of Science ®Google Scholar
• DAVIDSON DJ, DORIN JR, MCLACHLAN G et al.: Lung disease in the cystic fibrosis mouse exposed to bacterial pathogens. Nature Genet. (1995) 9:351–357.
   PubMed Web of Science ®Google Scholar
• COLLEDGE WH, ABELLA BS, SOUTHERN KW et al.: Generation and characterization of a delta F508 cystic fibrosis mouse model. Nature Genet. (1995) 10:445–452.
   PubMed Web of Science ®Google Scholar
• ZEIHER BG, EICHWALD E, ZABNER J et al: A mouse model for the delta F508 allele of cystic fibrosis. J. Clin. Invest. (1995) 96:2051–2064.
   PubMed Web of Science ®Google Scholar
• VAN DOORNINCK JH, FRENCH PJ, VERBEEK E et al.: A mouse model for the cystic fibrosis delta F508 mutation. EMBO J (1995) 14:4403–4411.
   PubMed Web of Science ®Google Scholar
• DELANEY SJ, ALTON EW, SMITH SN et al: Cystic fibrosis mice carrying the missense mutation G551D replicate human genotype-phenotype correlations. EMBO J. (1996) 15:955–963.
   PubMed Web of Science ®Google Scholar
• ILLEK B, ZHANG L, LEWIS NC, MOSS RB, DONG JY, FISCHER H: Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Am. J. Physiol. (1999) 277:C833–839.
   PubMed Web of Science ®Google Scholar
• HYDE SC, GILL DR, HIGGINS CF eta].: Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature (1993) 362:250–255.
   Google Scholar
• ALTON EW, MIDDLETON PG, CAPLEN NJ et al.: Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nature Genet. (1993) 5:135–142.
   PubMed Web of Science ®Google Scholar
• MCLACHLAN G, HO LP, DAVIDSON-SMITH H et al: Laboratory and clinical studies in support of cystic fibrosis gene therapy using pCMV-CFTR-DOTAP. Gene Ther. (1996) 3:1113–1123.
   PubMed Web of Science ®Google Scholar
• GODDARD CA, RATCLIFF R, ANDERSON JR et al: A second dose of a CFTR cDNA-liposome complex is as effective as the first dose in restoring cAMP-dependent chloride secretion to null CF mice trachea. Gene Ther. (1997) 4:1231–1236.
   PubMed Web of Science ®Google Scholar
• DORIN JR, FARLEY R, WEBB S et al: A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction. Gene Ther. (1996) 3:797–801.
   PubMed Web of Science ®Google Scholar
• JOHNSON LG, PICKLES RJ, BOYLES SE et al: In vitro assessment of variables affecting the efficiency and efficacy of adenovirus-mediated gene transfer to cystic fibrosis airway epithelia. Hum. Gene Ther. (1996) 7:51–59.
   PubMed Web of Science ®Google Scholar
• ZABNER J, COUTURE LA, GREGORY RJ, GRAHAM SM, SMITH AE, WELSH MJ: Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell (1993) 75:207–216.
   PubMed Web of Science ®Google Scholar
• CRYSTAL RG, MCELVANEY NG, ROSENFELD MA et al:Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Genet. (1994) 8:42–51.
   PubMed Web of Science ®Google Scholar
• KNOWLES MR, HOHNEKER KW, ZHOU Z et al.: A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl. J. Med. (1995) 333:823–831.
   PubMed Web of Science ®Google Scholar
• BELLON G, MICHEL-CALEMARD L, THOUVENOT D et al.:Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a Phase I clinical trial. Hum. Gene Ther. (1997) 8:15–25.
   PubMed Web of Science ®Google Scholar
• ZABNER J, RAMSEY BW, MEEKER DP et al: Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J. UM. Invest. (1996) 97:1504–1511.
   PubMed Web of Science ®Google Scholar
• WAGNER JA, REYNOLDS T, MORAN ML et al: Efficientand persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet (1998) 351:1702–1703.
   PubMed Web of Science ®Google Scholar
• CAPLEN NJ, ALTON EW, MIDDLETON PG et al.: Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nature Med. (1995) 1:39–46.
   PubMed Web of Science ®Google Scholar
• GILL DR, SOUTHERN KW, MOFFORD KA et al.: A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. (1997) 4:199–209.
   PubMed Web of Science ®Google Scholar
• PORTEOUS DJ, DORIN JR, MCLACHLAN G et al.: Evidencefor safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. (1997) 4:210–218.
   PubMed Web of Science ®Google Scholar
• ZABNER J, CHENG SH, MEEKER D et al: Comparison ofDNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. J. Clin. Invest. (1997) 100:1529–1537.
   PubMed Web of Science ®Google Scholar
• ALTON EW, STERN M, FARLEY R et al: Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet (1999) 353:947–954.
   PubMed Web of Science ®Google Scholar
• CHADWICK SL, KINGSTON HD, STERN M et al.: Safety of asingle aerosol administration of escalating doses of the cationic lipid GL-67/DOPE/DMPE-PEG5000 formulation to the lungs of normal volunteers. Gene Ther. (1997) 4:937–942.
   PubMed Web of Science ®Google Scholar
• YEW NS, WANG KX, PRZYBYLSKA M eta].: Contributionof plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes. Hum. Gene Ther. (1999) 10:223–234.
   Google Scholar
• STERN M, CAPLEN NJ, BROWNING JE et al: The effect ofmucolytic agents on gene transfer across a CF sputum barrier in vitro. Gene Ther. (1998) 5:91–98.
   PubMed Web of Science ®Google Scholar
• KITSON C, ANGEL B, JUDD D et al.: The extra- andintracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epithelium. Gene Ther. (1999) 6:534–546.
   PubMed Web of Science ®Google Scholar
• MORSY MA, CASKEY CT: Expanded-capacity adenoviral vectors- the helper-dependent vectors. Mol. Med. Today (1999) 5:18–24.
   PubMedGoogle Scholar
• SCHIEDNER G, MORRAL N, PARKS RJ et al: Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nature Genet. (1998) 18:180–183.
   PubMed Web of Science ®Google Scholar
• FLOTTE TR, AFIONE SA, SOLOW R et al: Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J. Biol. Chem. (1993) 268:3781–3790.
   PubMed Web of Science ®Google Scholar
• FLOTTE TR, AFIONE SA, CONRAD C et al.: Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc. Natl. Acad. ScL USA (1993) 90:10613–10617.
   PubMed Web of Science ®Google Scholar
• CONRAD CK, ALLEN SS, AFIONE SA et al.: Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther. (1996) 3:658–668.
   PubMed Web of Science ®Google Scholar
• TERAMOTO S, BARTLETT JS, MCCARTY D, XIAO X, SAMULSKI RJ, BOUCHER RC: Factors influencing adeno-associated virus-mediated gene transfer to human cystic fibrosis airway epithelial cells: comparison with adenovirus vectors. J. Virol. (1998) 72:8904–8912.
   PubMed Web of Science ®Google Scholar
• DUAN D, YUE Y, YAN Z, MCCRAY PB JR., ENGELHARDT JF: Polarity influences the efficiency of recombinant adenoassociated virus infection in differentiated airway epithelia. Hum. Gene Ther. (1998) 9:2761–2776.
   Google Scholar
• ZABNER J, SEILER M, WALTERS R et al.: Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J. Virol. (2000) 74:3852–3858.
   PubMed Web of Science ®Google Scholar
• FISHER KJ, JOOSS K, ALSTON J et al.: Recombinant adeno-associated virus for muscle directed gene therapy. Nature Med. (1997) 3:306–312.
   PubMed Web of Science ®Google Scholar
• HALBERT CL, STANDAERT TA, WILSON CB, MILLER AD: Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immuno-suppression during the initial exposure. J. Vim]. (1998) 72:9795–9805.
   Web of Science ®Google Scholar
• PARSONS DW, GRUBB BR, JOHNSON LG, BOUCHER RC: Enhanced in vivo airway gene transfer via transient modification of host barrier properties with a surface-active agent. Hum. Gene Ther. (1998) 9:2661–2672.
   PubMed Web of Science ®Google Scholar
• WANG G, ZABNER J, DEERING C et al: Increasing epithe-lial junction permeability enhances gene transfer to airway epithelia in vivo. Am. J. Respir. Cell Mol. Biol. (2000) 22:129–138.
   PubMed Web of Science ®Google Scholar
• SCHIAVI SC, ABDELKADER N, REBER S et al.: Biosynthetic and growth abnormalities are associated with high-level expression of CFTR in heterologous cells. Am. J. Physic)]. (1996) 270:C341–351.
   PubMed Web of Science ®Google Scholar
• STUTTS MJ, GABRIEL SE, OLSEN JC et al: Functional consequences of heterologous expression of the cystic fibrosis transmembrane conductance regulator in fibroblasts. J. Biol. Chem. (1993) 268:20653–20658.
   PubMed Web of Science ®Google Scholar
• QIN L, DING Y, PAHUD DR, CHANG E, IMPERIALE MJ, BROMBERG JS: Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum. Gene Ther. (1997) 8:2019–2029.
   PubMed Web of Science ®Google Scholar
• SUZUKI M, SINGH RN, CRYSTAL RG: Regulatablepromoters for use in gene therapy applications: modification of the 5'-flanking region of the CFTR gene with multiple cAMP response elements to support basal, low-level gene expression that can be upregulated by exogenous agents that raise intracel-lular levels of cAMP. Hum. Gene Ther. (1996) 7:1883–1893.
   PubMed Web of Science ®Google Scholar